{"id":61720,"date":"2025-08-13T01:05:49","date_gmt":"2025-08-12T23:05:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/"},"modified":"2025-08-13T01:05:49","modified_gmt":"2025-08-12T23:05:49","slug":"new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/","title":{"rendered":"New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management"},"content":{"rendered":"
\n

\nGroundbreaking research by Professor Richard Costello leads to innovative digital health platform<\/b><\/p>\n

DUBLIN–(BUSINESS WIRE)–Phyxiom<\/a>, a pioneering digital healthcare company, today announced its official launch, bringing transformative technology developed through extensive clinical research led by globally recognised respiratory specialist, Professor Richard Costello (RCSI University of Medicine and Health Sciences and Beaumont Hospital). Built upon groundbreaking studies published in Lancet Respiratory Medicine and validated by health economists, Phyxiom\u2019s platform provides clinicians with precise, real-time data to significantly enhance asthma and Chronic Obstructive Pulmonary Disease (COPD) management.<\/p>\n

<\/a>
<\/a><\/p>\n

\nCo-founded by experienced tech executive Grace O’Donnell as Chief Executive Officer and healthcare professional Elaine Mac Hale as Clinical Operations Director, along with Prof Costello, Phyxiom is a spin-out company from RCSI. Based on a strong foundational IP portfolio developed under an Enterprise Ireland (EI) Commercialisation Fund award the company has recently achieved EI High Potential Start- Up (HPSU) status. O’Donnell and Mac Hale lead Phyxiom\u2019s day-to-day operations, driving forward its mission to revolutionise respiratory healthcare through advanced digital solutions.<\/p>\n

\nProfessor Richard Costello, Chief Medical Officer at Phyxiom and Professor of Respiratory Medicine at RCSI, explained the science behind the innovation: \u201cOur research, spanning over a decade, has conclusively demonstrated that digitally-informed treatment significantly reduces medication use, prevents unnecessary hospitalisations, and ultimately lowers healthcare costs. By providing clinicians with objective, real-time insights into lung function and medication adherence, Phyxiom fundamentally improves diagnosis accuracy and treatment outcomes.\u201d<\/p>\n

\nPhyxiom\u2019s technology is already operational across 13 Health Service Executive (HSE) asthma clinics in Ireland, processing nearly 350 patients to date, with plans to expand further and engage Irish private health insurers in 2025.<\/p>\n

\nGrace O’Donnell, CEO, said: \u201cElaine and I are incredibly proud to lead this exciting RCSI spin-out company into the commercial market. We are passionate about using Richard\u2019s groundbreaking research as the foundation to deliver transformative, patient-centric healthcare solutions, significantly improving quality of life for patients suffering from uncontrolled asthma and COPD.\u201d<\/p>\n

\nElaine Mac Hale, Clinical Operations Director, added: \u201cPhyxiom seamlessly integrates into existing healthcare systems, ensuring minimal disruption to clinicians\u2019 workflows. Our evidence-based approach empowers healthcare providers with the insights needed to deliver personalised, effective, and efficient patient care.\u201d<\/p>\n

\nFollowing its successful Irish rollout, Phyxiom is expanding into the UK market in H1 2026 and plans a US launch in 2027, supported by established partnerships and integration with leading electronic health record systems.<\/p>\n

\nPhyxiom\u2019s launch marks a significant milestone in Ireland\u2019s healthtech landscape, highlighting Irish innovation on the global healthcare stage.<\/p>\n

\nThose interested in learning more about Phyxiom, can visit the website here: https:\/\/phyxiom.com\/<\/a><\/p>\n

\nAbout RCSI University of Medicine and Health Sciences<\/b><\/p>\n

\nRCSI University of Medicine and Health Sciences is ranked first in the world for its contribution to UN Sustainable Development Goal 3, Good Health and Well-being, in the Times Higher Education (THE) University Impact Rankings 2025.<\/p>\n

\nFounded in 1784 as the Royal College of Surgeons in Ireland with responsibility for training surgeons in Ireland, today RCSI is an innovative, not-for-profit, international university exclusively focused on driving improvements in human health worldwide through education, research and engagement.<\/p>\n

\nRCSI is among the top 300 universities worldwide in the World University Rankings (2025) and has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education.<\/p>\n

\nIn 2026, RCSI will open a new public engagement space, dedicated to health and well-being, at 118 St Stephen\u2019s Green in Dublin city centre. The space is designed to engage the public in dialogue about living longer, healthier and happier lives through dynamic events and exhibitions. Our aim is to bridge the gap between health sciences research, professional expertise, and public understanding, empowering people to make informed decisions about their health.<\/p>\n

\nVisit the RCSI MyHealth Expert Directory<\/a> to find the details of our experts across a range of healthcare issues and concerns. Recognising their responsibility to share their knowledge and discoveries to empower people with information that leads them to better health, these clinicians and researchers are willing to engage with the media in their area of expertise.<\/p>\n

Contacts<\/b> <\/p>\n

\nphyxiom@milkandhoneypr.com<\/a> or call Lewis Oakley or Kirsty Leighton on +44 20 3637 7310<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Groundbreaking research by Professor Richard Costello leads to innovative digital health platform DUBLIN–(BUSINESS WIRE)–Phyxiom, a pioneering digital healthcare company, today announced its official launch, bringing transformative technology developed through extensive clinical research led by globally recognised respiratory specialist, Professor Richard Costello (RCSI University of Medicine and Health Sciences and Beaumont Hospital). Built upon groundbreaking studies … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61720","6":"format-standard","7":"category-industry"},"yoast_head":"\nNew Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Groundbreaking research by Professor Richard Costello leads to innovative digital health platform DUBLIN–(BUSINESS WIRE)–Phyxiom, a pioneering digital healthcare company, today announced its official launch, bringing transformative technology developed through extensive clinical research led by globally recognised respiratory specialist, Professor Richard Costello (RCSI University of Medicine and Health Sciences and Beaumont Hospital). Built upon groundbreaking studies ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-12T23:05:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250812618079\/en\/2551399\/22\/phyxiom_horz.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management\",\"datePublished\":\"2025-08-12T23:05:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\\\/\"},\"wordCount\":685,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250812618079\\\/en\\\/2551399\\\/22\\\/phyxiom_horz.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\\\/\",\"name\":\"New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250812618079\\\/en\\\/2551399\\\/22\\\/phyxiom_horz.jpg\",\"datePublished\":\"2025-08-12T23:05:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250812618079\\\/en\\\/2551399\\\/22\\\/phyxiom_horz.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250812618079\\\/en\\\/2551399\\\/22\\\/phyxiom_horz.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/","og_locale":"en_US","og_type":"article","og_title":"New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management - Pharma Trend","og_description":"Groundbreaking research by Professor Richard Costello leads to innovative digital health platform DUBLIN–(BUSINESS WIRE)–Phyxiom, a pioneering digital healthcare company, today announced its official launch, bringing transformative technology developed through extensive clinical research led by globally recognised respiratory specialist, Professor Richard Costello (RCSI University of Medicine and Health Sciences and Beaumont Hospital). Built upon groundbreaking studies ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/","og_site_name":"Pharma Trend","article_published_time":"2025-08-12T23:05:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250812618079\/en\/2551399\/22\/phyxiom_horz.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management","datePublished":"2025-08-12T23:05:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/"},"wordCount":685,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250812618079\/en\/2551399\/22\/phyxiom_horz.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/","url":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/","name":"New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250812618079\/en\/2551399\/22\/phyxiom_horz.jpg","datePublished":"2025-08-12T23:05:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250812618079\/en\/2551399\/22\/phyxiom_horz.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250812618079\/en\/2551399\/22\/phyxiom_horz.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/new-irish-healthtech-firm-phyxiom-set-to-transform-asthma-and-copd-management\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61720"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61720\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61720"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61720"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}